Compare EIG & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | PHAR |
|---|---|---|
| Founded | 2000 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 980.0M | 1.1B |
| IPO Year | 2006 | 2020 |
| Metric | EIG | PHAR |
|---|---|---|
| Price | $42.45 | $16.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 172.8K | 9.0K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $858,700,000.00 | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | $1.26 | $2.51 |
| P/E Ratio | ★ $90.00 | $3,041.22 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.73 | $8.39 |
| 52 Week High | $49.98 | $21.34 |
| Indicator | EIG | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 56.83 | 49.59 |
| Support Level | $41.47 | $16.35 |
| Resistance Level | $43.01 | $17.49 |
| Average True Range (ATR) | 0.74 | 0.53 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 53.92 | 24.53 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations, through its wholly owned subsidiaries.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.